<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The p15INK4B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor is frequently silenced by promoter hypermethylation in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Clinically approved DNA methylation inhibitors, such as <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>, can reverse p15INK4B promoter methylation, but widespread clinical use of these inhibitors is limited by their toxicity and instability in aqueous solution </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="17562">cytidine</z:chebi> analog <z:chebi fb="0" ids="46938">zebularine</z:chebi> is a stable DNA methylation inhibitor that has minimal toxicity in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated <z:chebi fb="0" ids="46938">zebularine</z:chebi> effects on p15INK4B reactivation and cell growth in vitro to investigate a potential role for <z:chebi fb="0" ids="46938">zebularine</z:chebi> in treating <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We examined the specific effects of <z:chebi fb="0" ids="46938">zebularine</z:chebi> on reexpression of transcriptionally silenced p15INK4B and its global effects on cell cycle and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines and primary patient samples </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="46938">Zebularine</z:chebi> treatment of AML193, which has a densely methylated p15INK4B promoter, results in a dose-dependent increase in p15INK4B expression that correlates with CpG island promoter demethylation and enrichment of local <z:chebi fb="0" ids="15358">histone</z:chebi> acetylation </plain></SENT>
<SENT sid="6" pm="."><plain>We observed enhanced p15INK4B induction following co-treatment with <z:chebi fb="0" ids="46938">zebularine</z:chebi> and the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor <z:chebi fb="0" ids="46024">Trichostatin A</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="46938">Zebularine</z:chebi> inhibits cell proliferation, arrests cells at G(2)/M, and induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> at dosages that effectively demethylate the p15INK4B promoter </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="46938">Zebularine</z:chebi> treatment of KG-1 cells and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patient blasts with hypermethylated p15INK4B promoters also reactivates p15INK4B reexpression and induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="46938">Zebularine</z:chebi> is an effective inhibitor of p15INK4B methylation and cell growth in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in vitro </plain></SENT>
<SENT sid="10" pm="."><plain>Our results extend the spectrum of <z:chebi fb="0" ids="46938">zebularine</z:chebi> effects to nonepithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and provide a strong rationale for evaluating its clinical utility in the treatment of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>